Journal of Heart and Lung Transplantation

(The TQCC of Journal of Heart and Lung Transplantation is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal1206
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation297
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report — 2021; Focus on recipient charact215
A 5-year single-center early experience of heart transplantation from donation after circulatory-determined death donors150
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report—2020; focus on deceased donor characterist145
First cases of COVID-19 in heart transplantation from China134
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient charac131
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response109
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry106
Early US experience with cardiac donation after circulatory death (DCD) using normothermic regional perfusion103
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients101
Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium99
Donor heart and lung procurement: A consensus statement98
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients83
Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis83
MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry75
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience73
Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection71
COVID-19: Yet another coronavirus challenge in transplantation70
Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant65
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report — 2020; focus on deceased donor characteris60
Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial58
Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report58
Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation57
Artificial intelligence for early prediction of pulmonary hypertension using electrocardiography55
Pig-to-non-human primate heart transplantation: The final step toward clinical xenotransplantation?55
ISHLT consensus statement on donor organ acceptability and management in pediatric heart transplantation55
Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant53
Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients53
SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients49
Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement48
COVID-19 vaccination in our transplant recipients: The time is now47
Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial46
Heart transplantation following donation after circulatory death: Expanding the donor pool44
Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system44
Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States42
International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation42
The impact of frailty on mortality after heart transplantation40
ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association39
Increased early acute cellular rejection events in hepatitis C-positive heart transplantation39
Berlin Heart EXCOR and ACTION post-approval surveillance study report38
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study38
Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT36
Systemic ventricular assist device support in Fontan patients: A report by ACTION36
Lung transplantation for cystic fibrosis36
Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes36
Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study35
The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update35
COVID-19 in a lung transplant recipient34
Right ventricular function and cardiopulmonary performance among patients with heart failure supported by durable mechanical circulatory support devices34
Improved survival after heart transplantation in patients bridged with extracorporeal membrane oxygenation in the new allocation system33
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy32
Is it too early to investigate survival outcomes of the new US heart allocation system?32
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report—2022; focus on lung transplant reci32
Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study32
The results of a single-center experience with HeartMate 3 in a biventricular configuration32
First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany31
COVID-19 in a pediatric heart transplant recipient: Emergence of donor-specific antibodies31
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report — 2021; focus on recipient ch31
Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement30
Pregnancy outcomes in heart transplant recipients30
Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis30
Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis30
Outcomes in the 2018 UNOS donor heart allocation system: A perspective on disparate analyses30
Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension29
Cell-free DNA beyond a biomarker for rejection: Biological trigger of tissue injury and potential therapeutics28
Donor heart selection: Evidence-based guidelines for providers28
Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring28
Less invasive surgical implant strategy and right heart failure after LVAD implantation28
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial27
Prediction of donor related lung injury in clinical lung transplantation using a validated ex vivo lung perfusion inflammation score27
Cell death and ischemia-reperfusion injury in lung transplantation27
Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD)26
Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices – The CLEAR-LVAD study26
Mitochondrial transplantation for myocardial protection in ex-situ‒perfused hearts donated after circulatory death26
A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy26
Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation26
Expanding Heart Transplants from Donors After Circulatory Death (DCD) - Results of the First Randomized Controlled Trial Using the Organ Care System (OCS™) Heart - (OCS DCD Heart Trial)25
Challenges in heart transplantation during COVID-19: A single-center experience25
Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis25
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 23rd pediatric heart transplantation report—2020; focus on deceased donor characte25
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension24
COVID-19 vaccination immune paresis in heart and lung transplantation24
Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis24
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort23
Bridging the survival gap in cystic fibrosis: An investigation of lung transplant outcomes in Canada and the United States23
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report — 2021; Focus on recipient cha23
Ex situ heart perfusion: The past, the present, and the future23
The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support23
Clinical myocardial recovery in advanced heart failure with long term left ventricular assist device support22
Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment22
Percutaneous versus surgical cannulation for femoro-femoral VA-ECMO in patients with cardiogenic shock: Results from the Extracorporeal Life Support Organization Registry22
Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes22
Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction22
Variability in donor organ offer acceptance and lung transplantation survival22
International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document21
Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry21
Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases21
Clinical utility of donor-derived cell-free DNA testing in cardiac transplantation21
Comparison of combined heart‒liver vs heart-only transplantation in pediatric and young adult Fontan recipients21
Collapsing glomerulopathy associated with COVID-19 infection in a heart transplant recipient21
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis21
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-ninth adult heart transplantation report—2022; focus on transplant for rest21
Gender and racial disparities in lung transplantation in the United States20
Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment20
Elevated pulmonary arterial elastance and right ventricular uncoupling are associated with greater mortality in advanced heart failure20
Circulating miR-181a-5p as a new biomarker for acute cellular rejection in heart transplantation20
Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates20
A novel method of donor‒recipient size matching in pediatric heart transplantation: A total cardiac volume‒predictive model20
Preservation by cold storage vs ex vivo normothermic perfusion of marginal donor hearts: clinical, histopathologic, and ultrastructural features20
Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients20
Epicardial transplantation of atrial appendage micrograft patch salvages myocardium after infarction20
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study20
Bronchoalveolar bile acid and inflammatory markers to identify high-risk lung transplant recipients with reflux and microaspiration20
Long-term survival on LVAD support: Device complications and end-organ dysfunction limit long-term success19
Pig heart and lung xenotransplantation: Present status19
Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin19
Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation19
CFTR modulator use in post lung transplant recipients19
Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care19
Azithromycin prophylaxis after lung transplantation is associated with improved overall survival19
Percutaneous RVAD with the Protek Duo for severe right ventricular primary graft dysfunction after heart transplant18
Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease18
Use of metabolomics to identify strategies to improve and prolong ex vivo lung perfusion for lung transplants18
Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant18
Aspiration of conjugated bile acids predicts adverse lung transplant outcomes and correlates with airway lipid and cytokine dysregulation18
Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension17
Venous or arterial thromboses after venoarterial extracorporeal membrane oxygenation support: Frequency and risk factors17
Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy17
The lung microbiome in lung transplantation17
Therapeutic efficacy of large aligned cardiac tissue derived from induced pluripotent stem cell in a porcine ischemic cardiomyopathy model17
Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-1917
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery17
Outcomes based on blood pressure in patients on continuous flow left ventricular assist device support: An Interagency Registry for Mechanically Assisted Circulatory Support analysis17
Molecular T-cell‒mediated rejection in transbronchial and mucosal lung transplant biopsies is associated with future risk of graft loss17
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Twenty-fifth pediatric heart transplantation report—2022; focus on infant heart tr17
Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review16
Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis16
Influence of the donor history of tobacco and marijuana smoking on early and intermediate lung transplant outcomes16
Quantifying the impact from stroke during support with continuous flow ventricular assist devices: An STS INTERMACS analysis16
Innate allorecognition in transplantation16
Outcomes after heart transplantation and total artificial heart implantation: A multicenter study16
A current era analysis of ABO incompatible listing practice and impact on outcomes in young children requiring heart transplantation16
Risk factors of invasive fungal infections in lung transplant recipients: A systematic review and meta-analysis16
The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience16
An extracellular oxygen carrier during prolonged pulmonary preservation improves post-transplant lung function16
The influence of mechanical Circulatory support on post-transplant outcomes in pediatric patients: A multicenter study from the International Society for Heart and Lung Transplantation (ISHLT) Registr16
Adenosine A2A receptor agonist (regadenoson) in human lung transplantation16
Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart16
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement15
Exercise right ventricular ejection fraction predicts right ventricular contractile reserve15
Successful salvage therapy for fungal bronchial anastomotic infection after –lung transplantation with an inhaled triazole anti-fungal PC94515
Arterial oxygen and carbon dioxide tension and acute brain injury in extracorporeal cardiopulmonary resuscitation patients: Analysis of the extracorporeal life support organization registry15
Rotational thromboelastometry reduces blood loss and blood product usage after lung transplantation15
A challenge to equity in transplantation: Increased center-level variation in short-term mechanical circulatory support use in the context of the updated U.S. heart transplant allocation policy15
Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis15
Surveillance for cardiac allograft vasculopathy: Practice variations among 50 pediatric heart transplant centers15
Dilemma of organ donation in transplantation and the COVID-19 pandemic15
Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients15
A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation15
Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry15
Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?15
The impaired diaphragmatic function after bilateral lung transplantation: A multifactorial longitudinal study15
Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension14
Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry14
Two-year outcome of warfarin monotherapy in HeartMate 3 left ventricular assist device: A single-center experience14
Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age14
Pediatric heart transplantation following donation after circulatory death, distant procurement, and ex-situ perfusion14
A CLUE for better assessment of donor lungs: Novel technique in clinical ex vivo lung perfusion14
Use of direct oral anticoagulants after heart transplantation14
Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways14
High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients14
MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells14
Effects of cold or warm ischemia and ex-vivo lung perfusion on the release of damage associated molecular patterns and inflammatory cytokines in experimental lung transplantation14
Risk assessment in severe pulmonary hypertension due to interstitial lung disease14
Extended post ex-vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study14
Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative14
Myocardial edema in COVID-19 on cardiac MRI14
ISHLT position paper on thoracic organ transplantation in controlled donation after circulatory determination of death (cDCD)14
Lactate during ex-situ heart perfusion does not predict the requirement for mechanical circulatory support following donation after circulatory death (DCD) heart transplants14
Predicted heart mass–based size matching among recipients with moderate pulmonary hypertension: Outcomes and sex effect14
Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations13
Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension13
Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury13
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-third pediatric lung transplantation report — 2020; focus on deceased donor13
Impact of thoracotomy approach on right ventricular failure and length of stay in left ventricular assist device implants: an intermacs registry analysis13
Right ventricular area strain from 3-dimensional echocardiography: Mechanistic insight of right ventricular dysfunction in pediatric pulmonary hypertension13
Monitoring of perfusion quality and prediction of donor heart function during ex-vivo machine perfusion by myocardial microcirculation versus surrogate parameters13
A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective13
Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials13
Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial13
Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience13
Operating room extubation: A predictive factor for 1-year survival after double-lung transplantation13
Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients13
Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis13
Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters12
Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome12
Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy12
COVID-19 leading to acute encephalopathy in a patient with heart transplant12
Contemporary trends in PGD incidence, outcomes, and therapies12
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence12
ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, an12
Early United States experience with lung donation after circulatory death using thoracoabdominal normothermic regional perfusion12
WITHDRAWN: Executive Summary - The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients12
Ventilation in the prone position improves oxygenation and results in more lungs being transplanted from organ donors with hypoxemia and atelectasis12
The impact of pre-implant illness severity on the outcomes of pediatric patients undergoing durable ventricular assist device12
Preventing alloimmune rejection using circular RNA FSCN1-silenced dendritic cells in heart transplantation12
Pulmonary artery pulsatility index as a predictor of right ventricular failure in left ventricular assist device recipients: A systematic review12
Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension12
Temporal shift and predictive performance of machine learning for heart transplant outcomes12
Early report from the Pediatric Heart Transplant Society on COVID-19 infections in pediatric heart transplant candidates and recipients12
Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation12
Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort12
Donor thyroid hormone therapy and heart transplantation outcomes: ISHLT transplant registry analysis12
A simplified strategy for donor-recipient size-matching in lung transplant for interstitial lung disease12
Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation12
LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events12
International experience using a durable, centrifugal-flow ventricular assist device for biventricular support12
Precise treatment of acute antibody-mediated cardiac allograft rejection in rats using C4d-targeted microbubbles loaded with nitric oxide11
Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding11
Temporal trends in the use and outcomes of temporary mechanical circulatory support as a bridge to cardiac transplantation in Spain. Final report of the ASIS-TC study11
Approaches to the Management of Sensitized Lung Transplant Candidates: Findings from an International Survey11
Heart retransplantation following COVID-19 illness in a heart transplant recipient11
Inflammatory responses in lungs from donation after brain death: Mechanisms and potential therapeutic targets11
Higher levels of allograft injury in black patients early after heart transplantation11
First Results of Soprano: Macitentan in Patients (pts) with Pulmonary Hypertension (PH) Post-Left Ventricular Assist Device (LVAD) Implantation11
Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension11
Stroke in pediatric ventricular assist device patients—a pedimacs registry analysis11
Lung transplant outcome following donation after euthanasia11
Right single lung transplantation or double lung transplantation compared with left single lung transplantation in chronic obstructive pulmonary disease11
Biology of myocardial recovery in advanced heart failure with long-term mechanical support11
Circulating microRNAs in cellular and antibody-mediated heart transplant rejection11
Cardiac allograft vasculopathy and secondary outcomes of hepatitis C-positive donor hearts at 1 year after transplantation11
Association between recipient blood type and heart transplantation outcomes in the United States11
Bridging to transplant with HeartMate 3 left ventricular assist devices in the new heart organ allocation system: An individualized approach11
Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation11
Putting ethics and clinical decision making before politics: requiring COVID-19 immunization for Solid Organ Transplantation (SOT) Candidates and their Support Team11
Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device11
The heart–gut microbiome axis in advanced heart failure11
Remote ex vivo lung perfusion at a centralized evaluation facility11
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction11
Machine-learning–based exploration to identify remodeling patterns associated with death or heart-transplant in pediatric-dilated cardiomyopathy11
Immunologic risk stratification of pediatric heart transplant patients by combining HLAMatchmaker and PIRCHE-II11
The introduction of a super-urgent heart allocation scheme in the UK: A 2-year review11
Innate immunity in lung transplantation11
Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH10
Hemodynamic reserve predicts early right heart failure after LVAD implantation10
Patient factors associated with left ventricular assist device infections: A scoping review10
Lung transplantation disparities based on diagnosis for patients bridging to transplant on extracorporeal membrane oxygenation10
Residual mitral regurgitation in patients with left ventricular assist device support – An INTERMACS analysis10